Core Insights - IMUNON, Inc. is set to announce topline results from the Phase 2 OVATION 2 Study for its DNA-mediated immunotherapy, IMNN-001, targeting advanced ovarian cancer on July 30, 2024, at 8:00 a.m. Eastern time [3] - The company will host a conference call at 8:30 a.m. Eastern time to discuss the results and answer questions from the investment community [3][4] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases [5] - The company is advancing its non-viral DNA technology, with its first modality, TheraPlas®, designed for coding cytokines and therapeutic proteins for solid tumors [5] - The second modality, PlaCCine®, is aimed at delivering DNA-coded viral antigens to provoke strong immunological responses [5] Clinical Programs - The lead clinical program, IMNN-001, is a DNA-based immunotherapy in Phase 2 development for localized treatment of advanced ovarian cancer, which instructs the body to produce cancer-fighting molecules at the tumor site [6] - IMUNON has also initiated a first-in-human study for its COVID-19 booster vaccine, IMNN-101, indicating the company's commitment to advancing its technological capabilities in plasmid DNA [6]
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow